English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Immunomodulatory drugs such as interferon beta (IFN-beta) have modestly effective in relapsing remitting multiple sclerosis (RRMS). However, all current therapies are partially effective. The cause of MS and the determinants of heterogeneity in the clinical phenotype of MS remain largely unknown and new therapeutic approaches in MS are emerging. Even now, "bench to bed" is the only approach to find new therapies. However, we need to take part in exploring new therapies with the approach of "bench to bed and back". In the near future, studies on susceptibility genes and pharmacogenetics will provide invaluable information concerning new drugs for the treatment of MS and better therapeutic regimens for MS patients.

Approach to find new therapies for MS from clinical view